Retatrutide

Retatrutide (LY3437943) is an investigational unimolecular triple agonist that targets GLP-1, GIP, and glucagon receptors. In phase 2 clinical trials, it has demonstrated significant dose-dependent reductions in body weight, with participants achieving up to 24% weight loss over 48 weeks. Its triple mechanism of action addresses appetite regulation, insulin sensitivity, and energy expenditure simultaneously, making it one of the most potent weight-management compounds under investigation.